Grisell Ortiz Lasanta
Internal Medicine · San Juan, PRNPI 1538362918
Payments from drug & device makers
What this record shows
This record is dominated by travel and lodging: $3,135 of the $4,422 with a category attached, or 70.9%. Astrazeneca UK Limited accounts for 73.1% of it on its own, with 11 other manufacturers making up the rest. Reporting peaked in 2019 at $3,458 and has fallen 94.3% since, to $199 in 2023. Among internal medicine clinicians in PR with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 39 payments — averaging $113.37 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Astrazeneca UK Limited$3K
- Novartis$376
- Merck$234
- AbbVie$230
- Johnson & Johnson$100
- Janssen Research & Development, LLC$58
- plus $190 from 6 others
Across 1,660 payments — averaging $3533.32 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Regeneron$1.3M
- AbbVie$766K
- Boehringer Ingelheim International GmbH$620K
- GSK$543K
- Astrazeneca UK Limited$541K
- Madrigal Pharmaceuticals$519K
- plus $1.6M from 14 others
What the payments were for
- Travel & lodging$3,13571%
- Food & beverage$1,28729%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Astrazeneca UK Limited | 10 | $3,234 |
| Novartis | 3 | $376 |
| Merck | 2 | $234 |
| AbbVie(2 entities) | 9 | $230 |
| Johnson & Johnson | 6 | $100 |
| Janssen Research & Development, LLC | 1 | $58 |
| Taiho Oncology, Inc. | 3 | $54 |
| Intercept Pharmaceuticals, Inc. | 1 | $41 |
| Sanofi | 1 | $31 |
| E.r. Squibb & Sons, L.L.C. | 1 | $23 |
| Eisai Inc. | 1 | $22 |
| Amgen | 1 | $18 |
How this compares
$4,422 in reported general payments places this provider in the 90th percentile of 1,043 internal medicine providers in Puerto Rico.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Omega-3 Acid Ethyl Esters | 32 | $1,057 |
| Pantoprazole Sodium | 19 | $204 |
| Famotidine | 15 | $117 |
Paid to pharmacies, not to this prescriber.
Other internal medicine in San Juan
- Ricardo FernandezSan Juan$351K
- Norma SalgadoSan Juan$21K
- Victor Gordo GonzalezSan Juan$21K
- Roberto Calderon SantiagoSan Juan$20K
- Natalia Almodovar ArbeloSan Juan$9K
- Jeremy FelicianoSan Juan$8K
- Porfirio Diaz-RodriguezSan Juan$8K
- Pedro del Valle de TomasSan Juan$7K
- Rafael Figueroa NavarroSan Juan$6K
- Amilcar Torres FigueroaSan Juan$6K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.